The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms

Bibliography

• DEMYTTENAERE K, BRUFFAERTS R, POSADA-VILLA J et al.: Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA (2004) 291(21):2581-2590.
   PubMed Web of Science ®Google Scholar
• MUSSELMAN DL, EVANS DL, NEMEROFF CB: The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch. Gen. Psychiatry (1998) 55(7):580-592.
   PubMed Web of Science ®Google Scholar
• MUSSELMAN DL, GARLOW SJ, NEMEROFF CB: The neurochemistry of mood disorders: clinical studies. Neurobiology of Mental Illness (1999):348-364.
   Google Scholar
• MUSSELMAN DL, BETAN E, LARSEN H et al.: Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol. Psychiatry (2003) 54(3):317-329.
   PubMed Web of Science ®Google Scholar
• HORROBIN DF, BENNETT CN: Depression and bipolar disorder: relationships to impaired fatty acid and phospholipid metabolism and to diabetes, cardiovascular disease, immunological abnormalities, cancer, ageing and osteoporosis. Possible candidate genes. Prostaglandins Leukot. Essent. Fatty Acids (1999) 60(4):217-234.
   PubMed Web of Science ®Google Scholar
• LUSTMAN PJ, ANDERSON RJ, FREEDLAND KE et al.: Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care (2000) 23(7):934-942.
   PubMed Web of Science ®Google Scholar
• MCINTYRE RS, KONARSKI JZ, MISENER VL et al.: Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann. Clin. Psychiatry (2005) In Press.
   PubMedGoogle Scholar
• KOOY FH: Hyperglycemia in mental disorders. Brain (1919) 42:214-289.
   Google Scholar
• GUPTA B, AWASTHI A, and JAJU BP: Effect of acute & chronic imipramine treatment on glucose homeostasis. Indian J. Med. Res. (1992) 96:65-71.
   PubMed Web of Science ®Google Scholar
• DRYDEN S, FRANKISH HM, WANG Q et al.: The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats. Neuroscience (1996) 72(2):557-566.
   PubMed Web of Science ®Google Scholar
• GOMEZ R, HUBER J, LHULLIER F et al.: Plasma insulin levels are increased by sertraline in rats under oral glucose overload. Braz. J. Med. Biol. Res. (2001) 34(12):1569-1572.
   PubMed Web of Science ®Google Scholar
• ERENMEMISOGLU A, OZDOGAN UK, SARAYMEN R et al.: Effect of some antidepressants on glycaemia and insulin levels of normoglycaemic and alloxan-induced hyperglycaemic mice. J. Pharm. Pharmacol. (1999) 51(6):741-743.
   PubMed Web of Science ®Google Scholar
• PARK S, CHOI SB: Does fluoxetine administration influence insulin resistance in 90% pancreatectomized rats? Metabolism (2002) 51(1):38-43.
   PubMed Web of Science ®Google Scholar
• MCINTYRE RS, MANCINI DA, PEARCE MM et al.: Mood and psychotic disorders and Type 2 diabetes: a metabolic triad. Can. J. Diabetes (2005) 29(2):122-132.
   Google Scholar
• MCINTYRE RS, KONARSKI JZ, KECK PE: Psychotropic-induced weight gain: liability, mechanisms and treatment approaches. Obesity & Mental Disorders (2005) (14):307-352.
   Google Scholar
• PAILE-HYVARINEN M, WAHLBECK K, ERIKSSON JG: Quality of life and metabolic status in mildly depressed women with Type 2 diabetes treated with paroxetine: a single-blind randomised placebo controlled trial. BMC Fam. Pract. (2003) 4:7.
   PubMedGoogle Scholar
• LUSTMAN PJ, GRIFFITH LS, CLOUSE RE et al.: Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom. Med. (1997) 59(3):241-250.
   PubMed Web of Science ®Google Scholar
• WEBER-HAMANN B, WERNER M, HENTSCHEL F et al.: Metabolic changes in elderly patients with major depression: Evidence for increased accumulation of visceral fat at follow-up. Psychoneuroendocrinology (2005) Epub ahead of print.
   PubMedGoogle Scholar
• FAGIOLINI A, FRANK E, SCOTT JA et al.: Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. (2005) 7(5):424-430.
   PubMed Web of Science ®Google Scholar
• VAN PRAAG H, LEIJNSE B: The influence of some antidepressives of the hydrazine type on the glucose metabolism in depressed patients. Clin. Chim. Acta. (1963) 8:466-475.
   PubMed Web of Science ®Google Scholar
• VAN PRAAG HM, LEIJNSE B: The xylose metabolism in depressed patients and Its alterations under the influence of antidepressive hydrazines. Clin. Chim. Acta. (1965) 11:13-23.
   PubMed Web of Science ®Google Scholar
• GHAELI P, SHAHSAVAND E, MESBAHI M et al.: Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. J. Clin. Psychopharmacol. (2004) 24(4):386-388.
   PubMed Web of Science ®Google Scholar
• KATHOL RG, JAECKLE R, WYSHAM C et al.: Imipramine effect on hypothalamic-pituitary-adrenal axis response to hypoglycemia. Psychiatry Res. (1992) 41(1):45-52.
   PubMed Web of Science ®Google Scholar
• OKAMURA F, TASHIRO A, UTUMI A et al.: Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism (2000) 49(10):1255-1260.
   PubMed Web of Science ®Google Scholar
• SAARTO T, WIFFEN P: Antidepressants for neuropathic pain. Cochrane Database Syst. Rev. (2005) (3):CD005454.
   PubMedGoogle Scholar
• MAX MB, LYNCH SA, MUIR J et al.: Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N. Engl. J. Med. (1992) 326(19):1250-1256.
   PubMed Web of Science ®Google Scholar
• GOODNICK PJ: Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann. Clin. Psychiatry (2001) 13(1):31-41.
   PubMedGoogle Scholar
• HARVEY AT, RUDOLPH RL, and PRESKORN SH: Evidence of the dual mechanisms of action of venlafaxine. Arch. Gen. Psychiatry (2000) 57(5):503-509.
   PubMed Web of Science ®Google Scholar
• ROWBOTHAM MC, GOLI V, KUNZ NR et al.: Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain (2004) 110(3):697-706.
   PubMed Web of Science ®Google Scholar
• MCINTYRE RS, KONARSKI JZ: Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms. Expert Opin. Pharmacother. (2005) 6(5):707-713.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN DJ, LU Y, DETKE MJ et al.: Duloxetine versus placebo in patients with painful diabetic neuropathy. Pain (2005) 116(1-2):109-118.
   PubMed Web of Science ®Google Scholar
• RASKIN JW: Duloxetine does not affect glycemic control or lipid profiles in patients with diabetic neuropathic pain. Poster APA, Atlanta (2005).
   Google Scholar
• POTTER VAN LOON BJ, RADDER JK, FROLICH M et al.: Fluoxetine increases insulin action in obese Type II (non-insulin dependent) diabetic patients. Int. J. Obes. Relat.Metab. Disord. (1992) 16(Suppl. 4):S55-S61.
   PubMed Web of Science ®Google Scholar
• GRAY DS, FUJIOKA K, DEVINE W et al.: A randomized double-blind clinical trial of fluoxetine in obese diabetics. Int. J. Obes. Relat. Metab. Disord. (1992) 16(Suppl. 4):S67-S72.
   PubMedGoogle Scholar
• MAHEUX P, DUCROS F, BOURQUE J et al.: Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int. J. Obes. Relat. Metab. Disord. (1997) 21(2):97-102.
   PubMed Web of Science ®Google Scholar
• GOULD TD, ZARATE CA, MANJI HK: Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. J. Clin. Psychiatry (2004) 65(1):10-21.
   PubMed Web of Science ®Google Scholar
• MUELLER PS, HENINGER GR, MCDONALD RK: Insulin tolerance test in depression. Arch. Gen. Psychiatry (1969) 21(5):587-594.
   PubMed Web of Science ®Google Scholar
• GEENEN V, LANGER G, KOINIG G et al.: Release of human neurophysin I during insulin-induced hypoglycemia in depressed patients is abolished after recovery with clomipramine treatment. Psychoneuroendocrinology (1985) 10(1):61-69.
   PubMed Web of Science ®Google Scholar
• HORACEK J, KUZMIAKOVA M, HOSCHL C et al.: The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers. Psychoneuroendocrinology (1999) 24(8):785-797.
   PubMed Web of Science ®Google Scholar
• YANOVSKI SZ, YANOVSKI JA: Obesity. N. Engl. J. Med. (2002) 346(8):591-602.
   PubMed Web of Science ®Google Scholar
• JAIN AK, KAPLAN RA, GADDE KM et al.: Bupropion SR versus placebo for weight loss in obese patients with depressive symptoms. Obes. Res. (2002) 10(10):1049-1056.
   PubMedGoogle Scholar
• IBUKA N, KAWAMURA H: Loss of circadian rhythm in sleep-wakefulness cycle in the rat by suprachiasmatic nucleus lesions. Brain Res. (1975) 96(1):76-81.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO H, NAGAI K, NAKAGAWA H: Additional evidence that the suprachiasmatic nucleus is the center for regulation of insulin secretion and glucose homeostasis. Brain Res. (1984) 304(2):237-241.
   PubMed Web of Science ®Google Scholar
• LUSTMAN PJ, CLOUSE RE: Treatment of depression in diabetes: impact on mood and medical outcome. J. Psychosom. Res. (2002) 53(4):917-924.
   PubMed Web of Science ®Google Scholar
• LUSTMAN PJ, GRIFFITH LS, CLOUSE RE et al.: Psychiatric illness in diabetes mellitus. Relationship to symptoms and glucose control. J. Nerv. Ment. Dis. (1986) 174(12):736-742.
   PubMed Web of Science ®Google Scholar
• SAPOLSKY RM: Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch. Gen. Psychiatry (2000) 57(10):925-935.
   PubMed Web of Science ®Google Scholar
• MANJI HK, DREVETS WC, CHARNEY DS: The cellular neurobiology of depression. Nat. Med. (2001) 7(5):541-547.
   PubMed Web of Science ®Google Scholar
• MCEWEN BS: Mood disorders and allostatic load. Biol. Psychiatry (2003) 54(3):200-207.
   PubMed Web of Science ®Google Scholar
• BROWN ES, VARGHESE FP, MCEWEN BS: Association of depression with medical illness: does cortisol play a role? Biol. Psychiatry (2004) 55(1):1-9.
   PubMed Web of Science ®Google Scholar
• DANTZER R: Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur. J. Pharmacol. (2004) 500(1-3):399-411.
   PubMed Web of Science ®Google Scholar
• MAES M, BOSMANS E, CALABRESE J et al.: Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. (1995) 29(2):141-152.
   PubMed Web of Science ®Google Scholar
• TSAI SY, CHEN KP, YANG YY et al.: Activation of indices of cell-mediated immunity in bipolar mania. Biol. Psychiatry (1999) 45(8):989-994.
   PubMed Web of Science ®Google Scholar
• TSAI SY, YANG YY, KUO CJ et al.: Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. J. Affect. Disord. (2001) 64(2-3):185-193.
   PubMed Web of Science ®Google Scholar
• BREUNIS MN, KUPKA RW, NOLEN WA et al.: High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol. Psychiatry (2003) 53(2):157-165.
   PubMed Web of Science ®Google Scholar
• GREENBERG AS, MCDANIEL ML: Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of Type 2 diabetes. Eur. J. Clin. Invest. (2002) 32(Suppl. 3):24-34.
   PubMed Web of Science ®Google Scholar
• GRIMBLE RF: Inflammatory status and insulin resistance. Curr. Opin. Clin. Nutr. Metab Care (2002) 5(5):551-559.
   PubMed Web of Science ®Google Scholar
• DONATH MY, STORLING J, MAEDLER K et al.: Inflammatory mediators and islet beta-cell failure: a link between Type 1 and Type 2 diabetes. J. Mol. Med. (2003) 81(8):455-470.
   PubMed Web of Science ®Google Scholar
• KERN PA, RANGANATHAN S, LI C et al.: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. (2001) 280(5):E745-E751.
   PubMed Web of Science ®Google Scholar
• PAOLISSO G, RIZZO MR, MAZZIOTTI G et al.: Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha. Am. J. Physiol. (1998) 275(2 Pt 1):E294-E299.
   PubMed Web of Science ®Google Scholar
• HINZE-SELCH D, SCHULD A, KRAUS T et al.: Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology (2000) 23(1):13-19.
   PubMed Web of Science ®Google Scholar
• GIORGETTI M, TECOTT LH: Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. Eur. J. Pharmacol. (2004) 488(1-3):1-9.
   PubMed Web of Science ®Google Scholar
• ROWLAND NE, CARLTON J: Neurobiology of an anorectic drug: fenfluramine. Prog. Neurobiol. (1986) 27(1):13-62.
   PubMed Web of Science ®Google Scholar
• FERNSTROM JD, WURTMAN RJ: Brain serotonin content: physiological regulation by plasma neutral amino acids. Science (1972) 178(59):414-416.
   PubMed Web of Science ®Google Scholar
• JAMNICKY B, SLIJEPCEVIC M, HADZIJA M et al.: Tryptophan content in serum and brain of long-term insulin-treated diabetic rats. Acta Diabetol. Lat. (1991) 28(1):11-18.
   PubMedGoogle Scholar
• FUKAGAWA NK, MINAKER KL, ROWE JW et al.: Plasma tryptophan and total neutral amino acid levels in men: influence of hyperinsulinemia and age. Metabolism (1987) 36(7):683-686.
   PubMed Web of Science ®Google Scholar
• ASBERG M, THOREN P, TRASKMAN L et al.: ‘Serotonin depression’-a biochemical subgroup within the affective disorders? Science (1976) 191(4226):478-480.
   PubMed Web of Science ®Google Scholar
• CHAOULOFF F, LAUDE D, MERINO D et al.: Duration of streptozotocin diabetes influences the response of hypothalamic serotonin metabolism to immobilization stress. Neuroendocrinology (1989) 50(3):344-350.
   PubMed Web of Science ®Google Scholar
• CRANDALL EA, GILLIS MA, FERNSTROM JD: Reduction in brain serotonin synthesis rate in streptozotocin-diabetic rats. Endocrinology (1981) 109(1):310-312.
   PubMed Web of Science ®Google Scholar
• PESTELL RG, CROCK PA, WARD GM et al.: Fenfluramine increases insulin action in patients with NIDDM. Diabetes Care (1989) 12(4):252-258.
   PubMed Web of Science ®Google Scholar
• MAGARINOS AM, MCEWEN BS: Experimental diabetes in rats causes hippocampal dendritic and synaptic reorganization and increased glucocorticoid reactivity to stress. Proc. Natl. Acad. Sci. USA (2000) 97(20):11056-11061.
   PubMed Web of Science ®Google Scholar
• REAGAN LP, GOROVITS N, HOSKIN EK et al.: Localization and regulation of GLUTx1 glucose transporter in the hippocampus of streptozotocin diabetic rats. Proc. Natl. Acad. Sci. USA (2001) 98(5):2820-2825.
   PubMed Web of Science ®Google Scholar
• MCEWEN BS, ALVES SE, BULLOCH K et al.: Ovarian steroids and the brain: implications for cognition and aging. Neurology (1997) 48(5 Suppl. 7):S8-S15.
   PubMedGoogle Scholar
• MCEWEN BS, MAGARINOS AM, REAGAN LP: Studies of hormone action in the hippocampal formation: possible relevance to depression and diabetes. J. Psychosom. Res. (2002) 53(4):883-890.
   PubMed Web of Science ®Google Scholar
• CRAFT S, WATSON GS: Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. (2004) 3(3):169-178.
   PubMed Web of Science ®Google Scholar
• REGER MA, WATSON GS, FREY WH et al.: Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol. Aging (2005) Epub ahead of print.
   PubMedGoogle Scholar